Prostate specific antigen (PSA) is widely used as a serum marker to detect and monitor the progression of prostate cancer (PCa), and it has dramatically increased the rate of early detection and reduced PCa-specific mortality. This evidence concerns the gene KLK3 and prostate carcinoma.